{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:14:36Z","timestamp":1789496076058,"version":"build-2803163510"},"reference-count":32,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2023,10,3]]},"DOI":"10.1080\/14740338.2023.2221027","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T05:02:20Z","timestamp":1685941340000},"page":"995-1002","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world"],"prefix":"10.1080","volume":"22","author":[{"given":"Liesel","family":"Dsilva","sequence":"first","affiliation":[{"name":"Global Medical Safety, Biogen, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Drug Safety, Pharmacovigilance & Systems & Data Analytics, Biogen, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lyons","sequence":"additional","affiliation":[{"name":"Global Medical Safety, Biogen, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Cabigas","sequence":"additional","affiliation":[{"name":"Global Medical Safety, Biogen, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan","family":"Campbell","sequence":"additional","affiliation":[{"name":"Global Medical, Biogen, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kong","sequence":"additional","affiliation":[{"name":"Biostatistics, Biogen, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Adams","sequence":"additional","affiliation":[{"name":"Biostatistics, Biogen, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kuhelj","sequence":"additional","affiliation":[{"name":"Global Medical, Biogen, Baar, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Singhal","sequence":"additional","affiliation":[{"name":"Development, Biogen, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Smirnakis","sequence":"additional","affiliation":[{"name":"Safety and Benefit Risk Management, Biogen, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6,10]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322326"},{"issue":"7","key":"e_1_3_7_5_1","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1007\/s12325-021-01722-w","article-title":"Natalizumab in early relapsing-remitting multiple sclerosis: a 4-year, open-label study","volume":"38","author":"Perumal J","year":"2021","unstructured":"Perumal J, Balabanov R, Su R, et al. Natalizumab in early relapsing-remitting multiple sclerosis: a 4-year, open-label study. Adv Ther. 2021 Jul;38(7):3724\u20133742.","journal-title":"Adv Ther"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30282-X"},{"issue":"15","key":"e_1_3_7_8_1","first-page":"e1452","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Zhovtis Ryerson L","unstructured":"Zhovtis Ryerson L, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 1462 [2019 Sep 12];93(15):e1452\u2013e.","journal-title":"Neurology"},{"key":"e_1_3_7_9_1","unstructured":"Tysabri [Internet]. The Tysabri\u00ae (natalizumab) TOUCH\u00ae prescribing program Cambridge: MA: Biogen; 2022 [cited Mar 19 2022]. Available from: https:\/\/www.tysabrihcp.com\/en_us\/home\/touch-prescribing-program\/touch-online.html"},{"issue":"5","key":"e_1_3_7_10_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience","volume":"7","author":"Bomprezzi R","year":"2014","unstructured":"Bomprezzi R, Pawate S. Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord. 2014 Sep;7(5):227\u2013231.","journal-title":"Ther Adv Neurol Disord"},{"key":"e_1_3_7_11_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout BI","year":"2018","unstructured":"Yamout BI, Sahraian MA, Ayoubi NE, et al. Efficacy and safety of natalizumab extended interval dosing. Mult Scler Relat Disord. 2018 Aug;24:113\u2013116.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"e_1_3_7_12_1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s13311-019-00776-7","article-title":"Extending the interval of natalizumab dosing: is efficacy preserved?","volume":"17","author":"Clerico M","year":"2020","unstructured":"Clerico M, De Mercanti SF, Signori A, et al. Extending the interval of natalizumab dosing: is efficacy preserved? Neurotherapeutics. 2020 Jan;17(1):200\u2013207.","journal-title":"Neurotherapeutics"},{"issue":"8","key":"e_1_3_7_13_1","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson L","year":"2016","unstructured":"Zhovtis Ryerson L, Frohman TC, Foley J, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):885\u2013889.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117385"},{"key":"e_1_3_7_15_1","doi-asserted-by":"crossref","first-page":"103480","DOI":"10.1016\/j.msard.2021.103480","article-title":"No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: real-world evidence from MS PATHS","volume":"58","author":"Zhovtis Ryerson L","year":"2022","unstructured":"Zhovtis Ryerson L, Naismith RT, Krupp LB, et al. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: real-world evidence from MS PATHS. Mult Scler Relat Disord. 2022 Feb;58:103480.","journal-title":"Mult Scler Relat Disord"},{"key":"e_1_3_7_16_1","volume-title":"Presented at: 74th Annual Meeting of the American Academy of Neurology (AAN)","author":"Zhovtis Ryerson L","unstructured":"Zhovtis Ryerson L, Foley J, Chang I, et al. Natalizumab Extended Interval Dosing (EID) is associated with a reduced risk of Progressive Multifocal Leukoencephalopathy (PML) compared with every-4-week (Q4W) dosing: updated analysis of the TOUCH\u00ae prescribing program database. Presented at: 74th Annual Meeting of the American Academy of Neurology (AAN); Apr 2\u20137, 2022; Seattle, WA."},{"issue":"5","key":"e_1_3_7_17_1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/nmt.15.42","article-title":"Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen","volume":"5","author":"Herv\u00e1s JV","year":"2015","unstructured":"Herv\u00e1s JV, Presas-Rodr\u00edguez S, Crespo-Cuevas AM, et al. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen. Neurodegener Dis Manag. 2015 Oct;5(5):399\u2013402.","journal-title":"Neurodegener Dis Manag"},{"issue":"3","key":"e_1_3_7_18_1","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1212\/CPJ.0000000000000457","article-title":"Progressive multifocal leukoencephalopathy with extended natalizumab dosing","volume":"8","author":"Baldassari LE","year":"2018","unstructured":"Baldassari LE, Jones SE, Clifford DB, et al. Progressive multifocal leukoencephalopathy with extended natalizumab dosing. Neurol Clin Pract. 2018 Jun;8(3):e12\u2013e14.","journal-title":"Neurol Clin Pract"},{"issue":"10","key":"e_1_3_7_19_1","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s10072-019-03959-4","article-title":"Four cases of natalizumab-related PML: a less severe course in extended interval dosing?","volume":"40","author":"Scarpazza C","year":"2019","unstructured":"Scarpazza C, De Rossi N, Tabiadon G, et al. Four cases of natalizumab-related PML: a less severe course in extended interval dosing? Neurol Sci. 2019 Oct;40(10):2119\u20132124.","journal-title":"Neurol Sci"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000709"},{"key":"e_1_3_7_21_1","volume-title":"Presented at: 64th Annual Meeting of the American Academy of Neurology (AAN)","author":"Dong-Si T","unstructured":"Dong-Si T, Weber T, Richert N, et al. Classification of natalizumab case reports with progressive multifocal leukoencephalopathy. Presented at: 64th Annual Meeting of the American Academy of Neurology (AAN); Apr 21\u201328, 2012; New Orleans, LA."},{"issue":"1","key":"e_1_3_7_22_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1099\/vir.0.037440-0","article-title":"JC virus granule cell neuronopathy is associated with VP1 C terminus mutants","volume":"93","author":"Dang X","year":"2012","unstructured":"Dang X, Vidal JE, Penalva de Oliveira AC, et al. JC virus granule cell neuronopathy is associated with VP1 C terminus mutants. J Gen Virol. 2012 Jan;93(Pt 1):175\u2013183.","journal-title":"J Gen Virol"},{"issue":"1","key":"e_1_3_7_23_1","first-page":"S80","article-title":"Neurostatus and EDSS calculation with cases","volume":"55","author":"\u015een S.","year":"2018","unstructured":"\u015een S. Neurostatus and EDSS calculation with cases. Noro Psikiyatr Ars. 2018;55(Suppl 1):S80\u2013S83.","journal-title":"Noro Psikiyatr Ars"},{"key":"e_1_3_7_24_1","first-page":"191","volume-title":"Evaluation of chemotherapeutic agents","author":"Karnofsky DA","year":"1949","unstructured":"Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C, editor Evaluation of chemotherapeutic agents. (NY): Columbia University Press; 1949. p. 191\u2013205."},{"issue":"2","key":"e_1_3_7_25_1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneurol.2010.257","article-title":"Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy","volume":"68","author":"Miravalle A","year":"2011","unstructured":"Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011 Feb;68(2):186\u2013191.","journal-title":"Arch Neurol"},{"issue":"4","key":"e_1_3_7_26_1","first-page":"27","article-title":"Imaging findings for PML in natalizumab-treated MS patients","volume":"18","author":"Richert N","year":"2012","unstructured":"Richert N, Bloomgren G, Cadavid D. Imaging findings for PML in natalizumab-treated MS patients. Mult Scler. 2012;18(Suppl 4): 27\u201328. Oral 99.","journal-title":"Mult Scler"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-319208"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2670"},{"issue":"4","key":"e_1_3_7_29_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00415-015-8001-3","article-title":"Concomitant granule cell neuronopathy in patients with natalizumab-associated PML","volume":"263","author":"Wijburg MT","year":"2016","unstructured":"Wijburg MT, Siepman D, van Eijk JJ, et al. Concomitant granule cell neuronopathy in patients with natalizumab-associated PML. J Neurol. 2016 Apr;263(4):649\u2013656.","journal-title":"J Neurol"},{"issue":"3","key":"e_1_3_7_30_1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/WCO.0000000000000201","article-title":"Novel syndromes associated with JC virus infection of neurons and meningeal cells: no longer a gray area","volume":"28","author":"Miskin DP","year":"2015","unstructured":"Miskin DP, Koralnik IJ. Novel syndromes associated with JC virus infection of neurons and meningeal cells: no longer a gray area. Curr Opin Neurol. 2015 Jun;28(3):288\u2013294.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"e_1_3_7_31_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13365-016-0465-0","article-title":"JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7","volume":"23","author":"Soleimani-Meigooni DN","year":"2017","unstructured":"Soleimani-Meigooni DN, Schwetye KE, Angeles MR, et al. JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7. J Neurovirol. 2017 Feb;23(1):141\u2013146.","journal-title":"J Neurovirol"},{"issue":"4","key":"e_1_3_7_32_1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ana.23973","article-title":"JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment","volume":"74","author":"Schippling S","year":"2013","unstructured":"Schippling S, Kempf C, B\u00fcchele F, et al. JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol. 2013 Oct;74(4):622\u2013626.","journal-title":"Ann Neurol"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000713"},{"issue":"10","key":"e_1_3_7_34_1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/jnnp-2014-307582","article-title":"Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients","volume":"85","author":"Hoepner R","year":"2014","unstructured":"Hoepner R, Ahlbrecht J, Faissner S, et al. Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1177\u20131178.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2023.2221027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T08:58:34Z","timestamp":1695286714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2023.2221027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,3]]}},"alternative-id":["10.1080\/14740338.2023.2221027"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2023.2221027","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}